Abstract 497P
Background
Immune checkpoint inhibitors (ICIs) has been shown to be effective and has become the standard of care as first-line treatment of advanced NSCLC. Multiple previous studies of tumors have allowed the continued use of anti-PD-1 antibody therapy after first-line treatment progress. Subgroup analyses of these studies showed that 13-33% of patients receiving anti-PD-1 antibody therapy after progress achieved partial response (PR). The combination of ICIs and anti-angiogenic therapy has a synergistic anti-tumor effect and can improve the prognosis of patients. This study was designed to evaluate the efficacy and safety of sintilimab in combination with anlotinib in NSCLC disease progressed after first-line treatment with anti-PD-1 antibody.
Methods
An open, single-arm, phase II trial was designed, which enrolls NSCLC patients with disease progression after first-line treatment with anti-PD-1 antibody. Sintilimab (200 mg, day 1) in combination with anlotinib (12mg, day 1 to 14) were given every 3 weeks. Primary end point is objective response rate (ORR) evaluated via RECIST 1.1. Key secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR) and safety (CTCAE 5.0).
Results
From 3/2021 to 6/2023, 17 patients were enrolled. The median age was 63 years old (range 45-73) and 100% (17/17) was male. In 14 patients with efficacy data, 14.3% (2/14) achieved partial response (PR) and 71.4% (10/14) achieved stable disease (SD). ORR and DCR were 14.3% (and 85.7%, respectively. Until the last follow-up, the median PFS was 6.0 months(95% CI, range 4.2-7.7 months), 6-month PFS rate was 56.4%. The median OS was 17.9 months(95% CI, range 5.6-NA months), 12-month OS rate was 64.6%. Grade 3/4 treatment-related adverse events (TRAEs) included: hand and foot skin reaction (5.9%, 1/17), increased alanine aminotransferase (5.9%, 1/17), hypertension (11.8%, 2/17), hypertriglyceridemia (5.9%, 1/17) and neutropenia (5.9%, 1/17). No treatment-related deaths occurred.
Conclusions
Given the encouraging anti-tumor activity and favorable tolerability, the combination of sintilimab and anlotinib could be an effective and safe option for NSCLC.
Clinical trial identification
Clinical trial information: NCT04691388.
Editorial acknowledgement
Legal entity responsible for the study
Xinmin Yu.
Funding
1. Innovent Biologics, Inc. 2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract